Bosutinib-13C, d3

Bosutinib-13C, d3 (SKI-606-13C, d3) is 13C labeled Bosutinib. Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively[1].

Product Specifications

Product Name Alternative

SKI-606-13C, d3

UNSPSC

12352005

Target

Autophagy; Bcr-Abl; Isotope-Labeled Compounds; Src

Related Pathways

Autophagy; Others; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

N#CC1=CN=C2C=C(C(OC)=CC2=C1NC3=CC(O[13C]([2H])([2H])[2H])=C(C=C3Cl)Cl)OCCCN4CCN(CC4)C

Molecular Formula

C25 13CH26D3Cl2N5O3

Molecular Weight

534.46

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Jorge E Cortes, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30 (28) :3486-92.|[3]Miriam Puttini, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66 (23) :11314-22.